Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Sanara MedTech (SMTI) EBIT Margin (2016 - 2025)

Sanara MedTech's EBIT Margin history spans 15 years, with the latest figure at 3.81% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 478.0% year-over-year to 3.81%; the TTM value through Dec 2025 reached 1.82%, up 341.0%, while the annual FY2025 figure was 7.08%, 563.0% up from the prior year.
  • EBIT Margin reached 3.81% in Q4 2025 per SMTI's latest filing, down from 11.17% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 42.71% in Q4 2022 to a low of 35.55% in Q1 2022.
  • Average EBIT Margin over 5 years is 6.04%, with a median of 8.05% recorded in 2023.
  • Peak YoY movement for EBIT Margin: surged 5049bps in 2021, then tumbled -4399bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 32.7% in 2021, then skyrocketed by 31bps to 42.71% in 2022, then plummeted by -103bps to 1.28% in 2023, then soared by 773bps to 8.59% in 2024, then tumbled by -56bps to 3.81% in 2025.
  • Per Business Quant, the three most recent readings for SMTI's EBIT Margin are 3.81% (Q4 2025), 11.17% (Q3 2025), and 0.12% (Q2 2025).